A potentially game-changing has been granted approval for children living with (DMD).

In a ‘pivotal moment’ for people living with DMD, the Scottish Medical Consortium has approved the use of givinostat to treat children aged six and older who are still able to walk.

DMD is a rare genetic condition which causes progressive muscle weakness, eventually impacting the heart and lungs.

It is typically diagnosed in boys between the ages of 3 and 6.

While there is no cure, advocates for people living with the condition believe that givinostat can slow the progression of the disease, offering families precious time with their children.

The medicine, which was approved by the Medicines and Healthcare products Regulatory Agency (MHRA), blocks histone deacetylase – which is an enzy

See Full Page